Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Autoimmune Disorders

  Free Subscription


19.11.2018

2 Acta Neurol Scand
1 J Autoimmun
1 J Nephrol
1 J Neurol
1 Kidney Int
5 Mult Scler
1 Neurology
1 Thyroid


   Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Acta Neurol Scand

  1. BAYART JL, Muls N, van Pesch V
    Free Kappa light chains in neuroinflammatory disorders: Complement rather than substitute?
    Acta Neurol Scand. 2018;138:352-358.
    PubMed     Text format     Abstract available

  2. MELBYE P, Olsson A, Hansen TH, Sondergaard HB, et al
    Short-Chain Fatty Acids and Gut Microbiota in Multiple Sclerosis.
    Acta Neurol Scand. 2018 Nov 14. doi: 10.1111/ane.13045.
    PubMed     Text format     Abstract available


    J Autoimmun

  3. VAN DER MEULEN TA, Harmsen HJM, Vila AV, Kurilshikov A, et al
    Shared gut, but distinct oral microbiota composition in primary Sjogren's syndrome and systemic lupus erythematosus.
    J Autoimmun. 2018 Nov 9. pii: S0896-8411(18)30524.
    PubMed     Text format     Abstract available


    J Nephrol

  4. REYNOLDS ML, Nachman PH, Mooberry MJ, Crona DJ, et al
    Recurrent venous thromboembolism in primary membranous nephropathy despite direct Xa inhibitor therapy.
    J Nephrol. 2018 Nov 12. pii: 10.1007/s40620-018-0552.
    PubMed     Text format     Abstract available


    J Neurol

  5. BAUMGARTNER A, Rauer S, Hottenrott T, Leypoldt F, et al
    Admission diagnoses of patients later diagnosed with autoimmune encephalitis.
    J Neurol. 2018 Nov 12. pii: 10.1007/s00415-018-9105.
    PubMed     Text format     Abstract available


    Kidney Int

  6. ROVIN BH, Solomons N, Pendergraft WF 3rd, Dooley MA, et al
    A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis.
    Kidney Int. 2018 Nov 5. pii: S0085-2538(18)30628.
    PubMed     Text format     Abstract available


    Mult Scler

  7. FOX EJ, Markowitz C, Applebee A, Montalban X, et al
    Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial.
    Mult Scler. 2018 Nov 12:1352458518808189. doi: 10.1177/1352458518808189.
    PubMed     Text format     Abstract available

  8. RAATS J, Lamers I, Baert I, Willekens B, et al
    Cognitive-motor interference in persons with multiple sclerosis during five upper limb motor tasks with different complexity.
    Mult Scler. 2018 Nov 12:1352458518808194. doi: 10.1177/1352458518808194.
    PubMed     Text format     Abstract available

  9. LARONI A
    Enhancing natural killer cells is beneficial in multiple sclerosis - Yes.
    Mult Scler. 2018 Nov 13:1352458518800776. doi: 10.1177/1352458518800776.
    PubMed     Text format    

  10. LIU Q, Shi FD
    Enhancing natural killer cells is beneficial in multiple sclerosis - No.
    Mult Scler. 2018 Nov 13:1352458518799591. doi: 10.1177/1352458518799591.
    PubMed     Text format    

  11. SEGAL BM
    Enhancing natural killer cells is beneficial in multiple sclerosis - Commentary.
    Mult Scler. 2018 Nov 13:1352458518809296. doi: 10.1177/1352458518809296.
    PubMed     Text format    


    Neurology

  12. MARRIE RA, Butzkueven H, Ascherio A
    Obesity and brain volume loss in multiple sclerosis.
    Neurology. 2018 Nov 14. pii: WNL.0000000000006638.
    PubMed     Text format    


    Thyroid

  13. YOSHIHARA A, Iwaku K, Noh JY, Watanabe N, et al
    Incidence of neonatal hyperthyroidism among newborns of Graves' disease patients treated with radioiodine therapy.
    Thyroid. 2018 Nov 14. doi: 10.1089/thy.2018.0165.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: